Mustafeez Ur Rahman
Interventional Cardiology · Kalamazoo, MINPI 1174175376
Payments from drug & device makers
What this record shows
This record is dominated by grants: $4,667 of the $7,134 with a category attached, or 65.4%. 24 manufacturers reported payments, led by Abbott at 50.1% of the total. 2025 is the largest year on record at $6,895, more than ten times the $94 reported in 2022. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 62 payments — averaging $115.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$2K
- Abiomed$386
- Boston Scientific$288
- Stryker$265
- Penumbra, Inc.$212
- plus $801 from 18 others
What the payments were for
- Grants$4,66765%
- Food & beverage$2,46735%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $3,573 |
| Medtronic | 7 | $1,610 |
| Abiomed | 7 | $386 |
| Boston Scientific | 4 | $288 |
| Stryker | 6 | $265 |
| Penumbra, Inc. | 2 | $212 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $114 |
| Shockwave Medical, Inc | 2 | $112 |
| Biosense Webster, Inc. | 1 | $73 |
| Bridgebio Pharma, Inc. | 3 | $66 |
| Teleflex LLC | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| Cordis US CORP. | 2 | $41 |
| Amgen | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Cardiva Medical, Inc. | 1 | $33 |
| Chiesi USA, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| BD | 1 | $22 |
| Novartis | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Heartflow, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE V$3,333
- GENERAL VASCULAR ACCESS$196
- Ultreon$175
- SYMPLICITY G3$163
- Indigo System$143
- FlowTriever$139
How this compares
$7,134 in reported general payments places this provider in the 50th percentile of 187 interventional cardiology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $10,295 |
| Rosuvastatin Calcium | 30 | $409 |
| Metoprolol Succinate | 25 | $302 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $263 |
| ClopidogrelClopidogrel Bisulfate | 11 | $180 |
| Ezetimibe | 15 | $96 |
| Metoprolol Tartrate | 13 | $51 |
| Carvedilol | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Kalamazoo
- Tim FischellKalamazoo$468K
- Vishal GuptaKalamazoo$293K
- Frank SaltielKalamazoo$20K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.